Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
NEJM 2025 (REDEFINE-2) Novo Nordisk FDA NDA submission announcement (December 18, 2025) Eli Lilly TRIUMPH-4 topline results (December 2025) Frequently Asked Questions Retatrutide produces higher weight loss at 28.7% versus CagriSema's 20.4%a difference of 21 pounds for a 250-pound person
Month 3 Summary: The Transformation Begins Weight loss: 4-8 pounds this month (15-19 pounds total, 7-9% of starting weight) Side effects: Dramatically improved from month 2 Energy: Normalized to near-baseline levels Discontinuation rate: Only 2-3% stop during month 3 (completion probability high) Psychological state: Confident, encouraged, sustainable feeling Key achievement: Completed dose escalation successfully
We use: Slowly reducing the medicine Watching platelet counts closely during this time Thinking about other treatments to keep platelets stable These steps help avoid bad reactions and make stopping treatment smoother for patients
Polycystic ovary syndrome is the most common endocrine disorder in reproductive-age women, and its increasingly understood as a metabolic condition rooted in insulin resistance not simply a reproductive one
Instead of rapid results, expect a slow and steady pace that supports long-term success
